Editas Medicine Inc - Company Profile
Powered by 
All the sales intelligence you need on Editas Medicine Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Editas Medicine Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Editas Medicine Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Editas Medicine Inc (Editas Medicine) formerly Gengine Inc, is a discovery phase biotechnology company that develops therapies based on CRISPR- gene editing technology using Cas9 and Cas12a enzymes for the treatment of serious diseases. Focus on research and development activities, proprietary genome editing platform, and strategic partnerships are its strengths, even as decline in profitability is a major cause of concern to the company. Although intense competition, dependence on third party manufacturers, and government regulations could hamper the company's growth prospects, Editas Medicine could benefit from expanding gene editing platform through in-licensing, growing market for cancer treatments, and strategic collaborations and licensing agreements.
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer